Why is Glaxosmi. Pharma falling/rising?

As of 15-Sep, Glaxosmithkline Pharmaceuticals Ltd is experiencing a decline in its stock price, currently at 2,752.00, which reflects a decrease of 22.95 points or 0.83%. The stock has underperformed its sector by 0.38% today and has been on a consecutive downward trend for the last two days, resulting in a total drop of 3.72%. Over the past week, the stock has decreased by 2.11%, and on a yearly basis, it has fallen by 4.94%. Despite these recent declines, the company shows strong fundamentals with a high return on equity (ROE) of 42.32% and a low debt-to-equity ratio, indicating solid management efficiency and financial stability.
Broader market context reveals that while Glaxosmithkline's stock has struggled recently, the benchmark Sensex has performed positively, gaining 1.24% over the past week and 1.47% over the past month. This contrast highlights the stock's underperformance relative to the broader market. Additionally, the rising investor participation, as evidenced by a significant increase in delivery volume, suggests that there may be interest in the stock despite its current price decline. Overall, the stock's recent movement appears to be influenced by short-term market pressures rather than long-term fundamentals, as indicated by its strong historical performance over three and five years compared to the benchmark.